Lista de obras -

185 Peptide Vaccine Therapy for Childhood Gliomas

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model

artículo científico publicado en 2002

ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS

ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Actively personalized vaccination trial for newly diagnosed glioblastoma

scientific article published on 19 December 2018

Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.

artículo científico publicado en 2006

Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem

artículo científico publicado en 2014

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

artículo científico publicado en 2016

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

artículo científico publicado en 2017

Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics

artículo científico publicado en 2007

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas

artículo científico publicado en 2007

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy

artículo científico publicado en 2003

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy

artículo científico publicado en 2014

COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells ⬇️

artículo científico publicado el 15 de febrero de 2011

Classification of current anticancer immunotherapies

artículo científico publicado en 2014

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

artículo científico publicado en 2014

Considerations when treating high-grade pediatric glioma patients with immunotherapy

artículo científico publicado en 2020

Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways

artículo científico publicado en 2005

Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines

scientific article published on 01 August 2004

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

artículo científico publicado en 2011

Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine

artículo científico publicado en 2016

Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.

artículo científico publicado en 2009

Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma

artículo científico publicado en 2012

Do we need novel radiologic response criteria for brain tumor immunotherapy?

artículo científico publicado en 2011

Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

artículo científico publicado en 2009

Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells

artículo científico publicado en 2003

Ependymomas: development of immunotherapeutic strategies.

artículo científico publicado en 2013

EphA2 as a glioma-associated antigen: a novel target for glioma vaccines

artículo científico publicado en 2005

Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors

artículo científico publicado en 2005

Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival

artículo científico publicado en 2015

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

artículo científico publicado en 2016

Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo

artículo científico publicado en 2003

Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.

artículo científico publicado en 2008

Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model

artículo científico publicado en 2017

GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

artículo científico publicado en 2013

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy

HG-81NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION.

artículo científico publicado en 2016

Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity

artículo científico publicado en 2007

Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas

artículo científico publicado en 2015

Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines

article

IB-03IDH MUTANT GLIOMAS ARE RESISTANT TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS.

artículo científico publicado en 2014

IB-09STING AGONIST INDUCES POTENT ANTI-GLIOMA IMMUNITY VIA INDUCTION OF TYPE-I IFN SIGNALS IN THE TUMOR MICROENVIRONMENT

artículo científico publicado en 2014

IDH mutation-induced suppression of type-1 anti-glioma immune response.

artículo científico publicado en 2015

IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit

artículo científico publicado en 2008

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors

artículo científico publicado en 2009

IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity

artículo científico publicado en 2005

IM-03SERIAL METABOLISM OF DIFFUSE INTRINSIC PONTINE GLIOMA TREATED WITH PEPTIDE BASED VACCINE THERAPY.

artículo científico publicado en 2015

IMMU-04. OVERCOMING IMMUNE EVASION IN GLIOBLASTOMA

IMMU-17. PEPTIDE VACCINE IMMUNOTHERAPY BIOMARKERS AND RESPONSE PATTERNS IN PEDIATRIC GLIOMAS

IMMU-18. TARGETING H3.3 K27M MUTATION AS A SHARED NEOANTIGEN IN HLA-A*0201+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS – DEVELOPMENT OF A NOVEL MASS CYTOMETRY-BASED MONITORING OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T CELL RESPONSES

scholarly article

IMMU-26. PEPTIDE VACCINE IMMUNOTHERAPY BIOMARKERS AND RESPONSE PATTERNS IN PEDIATRIC GLIOMAS

IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN – CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY

scholarly article

IMMU-42. ONO-AE3-208 PROMOTES ANTI-TUMOR IMMUNE ACTIVITY AND SURVIVAL IN GLIOMA MODELS

artículo científico publicado en 2017

IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES

IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION

article by Payal Watchmaker et al published 5 November 2018 in Neuro-Oncology

IMPS-11EXPRESSION AND PROGNOSTIC IMPACT OF IMMUNE MODULATORY MOLECULE PD-L1 IN MENINGIOMA.

artículo científico publicado en 2015

IMPS-19RETROVIRAL REPLICATING VECTOR-MEDIATED DELIVERY OF AN IMMUNODOMINANT NEO-ANTIGEN EPITOPE TARGET FOR VIRO-IMMUNOTHERAPY IN EXPERIMENTAL GLIOMA.

artículo científico publicado en 2015

IMPS-30NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION.

artículo científico publicado en 2015

IT-17ONO-AE3-208 INHIBITS MYELOID-DERIVED SUPPRESSOR CELLS AND GLIOMA GROWTH.

artículo científico publicado en 2014

IT-23INDUCTION OF ROBUST TYPE-1 CD8+ T-CELL RESPONSES IN WHO GRADE II LOW-GRADE GLIOMA PATIENTS RECEIVING PEPTIDE-BASED VACCINES IN COMBINATION WITH POLY-ICLC.

artículo científico publicado en 2014

IT-33USE OF IFN-ALPHA AND POLY-ICLC AS CHEMOKINE MODULATORS FOR IMMUNOTHERAPY IN GLIOMAS.

artículo científico publicado en 2014

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

artículo científico publicado en 2018

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

artículo científico publicado en 2019

Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain

artículo científico publicado en 2002

Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

artículo científico publicado en 2006

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas

artículo científico publicado en 2016

Immune-checkpoint blockade and active immunotherapy for glioma

artículo científico publicado en 2013

Immunotherapeutic approaches for glioma

artículo científico publicado en 2009

Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons

scientific article published on 21 January 2019

Immunotherapy of Primary Brain Tumors: Facts and Hopes

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

artículo científico publicado en 2015

In Vivo Intracellular Oxygen Dynamics in Murine Brain Glioma and Immunotherapeutic Response of Cytotoxic T Cells Observed by Fluorine-19 Magnetic Resonance Imaging ⬇️

artículo científico publicado el 8 de mayo de 2013

Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy ⬇️

artículo científico publicado el 21 de noviembre de 2012

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

artículo científico publicado en 2010

Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

artículo científico publicado en 2014

Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma

artículo científico publicado en 2008

Integration of epidemiology, immunobiology, and translational research for brain tumors

artículo científico publicado en 2013

Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.

artículo científico publicado en 2003

Introduction to immunotherapy for brain tumor patients: challenges and future perspectives

artículo científico publicado en 2020

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

artículo científico publicado en 2017

MTR-01BEVACIZUMAB-INDUCED MIF DEPLETION: A NOVEL RESISTANCE MECHANISM IN GLIOBLASTOMA.

artículo científico publicado en 2015

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

scientific article published on 20 August 2020

MicroRNAs and STAT interplay.

artículo científico publicado en 2011

MicroRNAs in immune regulation--opportunities for cancer immunotherapy

artículo científico publicado en 2010

Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.

artículo científico publicado en 2012

NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP.

artículo científico publicado en 2015

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience

artículo científico publicado en 2017

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

artículo científico publicado en 2017

Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation.

artículo científico publicado en 2015

ONO-AE3-208 inhibits myeloid derived suppressor cells and glioma growth

Peptide Vaccine Therapy for Childhood Gliomas ⬇️

artículo científico publicado el 1 de agosto de 2013

Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.

artículo científico publicado en 2018

Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A24/A02 allele.

artículo científico publicado en 2012

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

scientific article published on 29 November 2019

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners

artículo científico publicado en 2010

Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors

scientific article published on 01 July 2007

Premetastatic soil and prevention of breast cancer brain metastasis

artículo científico publicado en 2013

Principles of immunology and its nuances in the central nervous system

artículo científico publicado en 2015

Prioritization schema for immunotherapy clinical trials in glioblastoma

scientific article published on 18 February 2016

Promise and challenges of peptide-poly: ICLC vaccines for adult and pediatric gliomas

artículo científico publicado en 2013

Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy

artículo científico publicado en 2015

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

scientific article published on 01 February 2019

ROBUST INDUCTION OF TYPE-1 CD8+ T-CELL RESPONSES IN WHO GRADE II LOW-GRADE GLIOMA PATIENTS RECEIVING PEPTIDE-BASED VACCINES IN COMBINATION WITH POLY-ICLC.

artículo científico publicado en 2014

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

artículo científico publicado en 2015

Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials

artículo científico publicado en 2015

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models

scientific article published on 05 September 2018

Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans

artículo científico publicado en 2010

STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment

STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment

artículo científico publicado en 2014

Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.

artículo científico publicado en 2007

Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.

scientific article published on July 2008

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy ⬇️

artículo científico publicado el 30 de noviembre de 2010

Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines

scientific article published on 27 October 2009

T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment

artículo científico publicado en 2020

TMIC-11. TUMOR GENETICS AND MACROPHAGE ONTOGENY SHAPE THE INNATE IMMUNE RESPONSE TO GLIOMA

artículo científico publicado en 2017

The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019

artículo científico publicado en 2020

The current state of immunotherapy for primary and secondary brain tumors: similarities and differences

scientific article published on 28 September 2020

The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion

scientific article published on 27 February 2019

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

artículo científico publicado en 2007

Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity

artículo científico publicado en 2015

Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy

artículo científico publicado en 2007

Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy

artículo científico publicado en 2019

Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology ⬇️

artículo científico publicado en 2020

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

artículo científico publicado en 2004

Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice

artículo científico publicado en 2012

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma

artículo científico publicado en 2019

Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011 ⬇️

artículo científico publicado el 28 de mayo de 2012

miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy

artículo científico publicado en 2010

Lista de obras de

185 Peptide Vaccine Therapy for Childhood Gliomas

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model

ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS

ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Actively personalized vaccination trial for newly diagnosed glioblastoma

Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.

Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy

COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells ⬇️

Classification of current anticancer immunotherapies

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

Considerations when treating high-grade pediatric glioma patients with immunotherapy

Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways

Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine

Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.

Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma

Do we need novel radiologic response criteria for brain tumor immunotherapy?

Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells

Ependymomas: development of immunotherapeutic strategies.

EphA2 as a glioma-associated antigen: a novel target for glioma vaccines

Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors

Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo

Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.

Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model

GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy

HG-81NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION.

Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity

Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas

Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines

IB-03IDH MUTANT GLIOMAS ARE RESISTANT TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS.

IB-09STING AGONIST INDUCES POTENT ANTI-GLIOMA IMMUNITY VIA INDUCTION OF TYPE-I IFN SIGNALS IN THE TUMOR MICROENVIRONMENT

IDH mutation-induced suppression of type-1 anti-glioma immune response.

IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors

IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity

IM-03SERIAL METABOLISM OF DIFFUSE INTRINSIC PONTINE GLIOMA TREATED WITH PEPTIDE BASED VACCINE THERAPY.

IMMU-04. OVERCOMING IMMUNE EVASION IN GLIOBLASTOMA

IMMU-17. PEPTIDE VACCINE IMMUNOTHERAPY BIOMARKERS AND RESPONSE PATTERNS IN PEDIATRIC GLIOMAS

IMMU-18. TARGETING H3.3 K27M MUTATION AS A SHARED NEOANTIGEN IN HLA-A*0201+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS – DEVELOPMENT OF A NOVEL MASS CYTOMETRY-BASED MONITORING OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T CELL RESPONSES

IMMU-26. PEPTIDE VACCINE IMMUNOTHERAPY BIOMARKERS AND RESPONSE PATTERNS IN PEDIATRIC GLIOMAS

IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN – CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY

IMMU-42. ONO-AE3-208 PROMOTES ANTI-TUMOR IMMUNE ACTIVITY AND SURVIVAL IN GLIOMA MODELS

IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES

IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION

IMPS-11EXPRESSION AND PROGNOSTIC IMPACT OF IMMUNE MODULATORY MOLECULE PD-L1 IN MENINGIOMA.

IMPS-19RETROVIRAL REPLICATING VECTOR-MEDIATED DELIVERY OF AN IMMUNODOMINANT NEO-ANTIGEN EPITOPE TARGET FOR VIRO-IMMUNOTHERAPY IN EXPERIMENTAL GLIOMA.

IMPS-30NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION.

IT-17ONO-AE3-208 INHIBITS MYELOID-DERIVED SUPPRESSOR CELLS AND GLIOMA GROWTH.

IT-23INDUCTION OF ROBUST TYPE-1 CD8+ T-CELL RESPONSES IN WHO GRADE II LOW-GRADE GLIOMA PATIENTS RECEIVING PEPTIDE-BASED VACCINES IN COMBINATION WITH POLY-ICLC.

IT-33USE OF IFN-ALPHA AND POLY-ICLC AS CHEMOKINE MODULATORS FOR IMMUNOTHERAPY IN GLIOMAS.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain

Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas

Immune-checkpoint blockade and active immunotherapy for glioma

Immunotherapeutic approaches for glioma

Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons

Immunotherapy of Primary Brain Tumors: Facts and Hopes

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

In Vivo Intracellular Oxygen Dynamics in Murine Brain Glioma and Immunotherapeutic Response of Cytotoxic T Cells Observed by Fluorine-19 Magnetic Resonance Imaging ⬇️

Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy ⬇️

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma

Integration of epidemiology, immunobiology, and translational research for brain tumors

Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.

Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A24/A02 allele.